<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016469</url>
  </required_header>
  <id_info>
    <org_study_id>IBDBP-1</org_study_id>
    <nct_id>NCT02016469</nct_id>
  </id_info>
  <brief_title>Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation</brief_title>
  <official_title>A Randomized, Controlled, Single-blind Study of Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation to Patients With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect and safety of pectin and fecal microbiota
      transplantation on patients with inflammatory bowel disease. The investigators hypothesize
      that patients who take pectin can promote the migration of probiotics in intestine
      engraftment, reduce pathogenic agents'adhesion to intestinal mucosa, cut down the
      inflammation, and to maintain intestinal flora diversity and steady state in a long time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory bowel disease (IBD) is a chronic relapsing disease, including ulcerative colitis
      (UC) and Crohn's disease (CD). Although the etiology of IBD is unknown, but more and more
      evidence show that the inappropriate immune response to intestinal commensal bacteria leading
      to dysbiosis, and pathogens further act to the mucosal lymphoid tissue, causing IBD. Has yet
      not to determine the specific one or more pathogens as the cause of IBD,but literatures
      confirm the changes of diversity of the intestine flora.Based on the current awareness of
      changes in the intestinal flora in IBD, fecal microbiota transplantation (FMT) proposed in
      recent years to rebuild the intestine flora balance to achieve therapeutic purposes. But
      fecal bacteria of patients can not consistent with donor's for a long term after
      transplantation and therefore it is not an ideal way for disease control. Maintaining the
      diversity of flora in a long time so that well controlled the disease become the breakthrough
      of fecal microbiota transplantation in the treatment of inflammatory bowel disease.

      Pectin is a soluble dietary fiber (DF), produced by the gut flora after a series of
      fermentation with many metabolites such as short chain fatty acids (SCFA) which supply the
      energy for epithelial cells, regulate intestinal PH and intestinal motility and join effort
      in immune regulation with intestinal lymphoid tissue. Previous studies showed that:
      water-soluble dietary fiber with the action of intestinal flora can cut the inflammatory
      cytokines, prevent inflammation and induce regulatory T cells, but the type and dose of
      dietary fiber used were different in different studies, and no studies have confirmed whether
      dietary fiber could adjusted the flora colonization ability in patients with IBD. We conceive
      that pectin by some mechanism to promote the migration of probiotics in intestine
      engraftment, reduce pathogenic agents' adhesion of intestinal mucosa, cut inflammation, and
      to maintain intestinal flora diversity and steady state in a long time, and than achieve the
      goal of continue to ease IBD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diversity and steady state of the stool</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in diversity and steady state of the stool every week within one month after the intervention and three and six months after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte sedimentation rate</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in ESR 1st,3st,6st month after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in CRP 1st,3st,6st month after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calcium protein</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in Fecal calcium protein 1st,3st,6st month after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions after fecal microbiota transplantation and/or take pectin</measure>
    <time_frame>1 week</time_frame>
    <description>every day within one week after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's disease activity index</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in CDAI two weeks,one,three and six months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulcerative Colitis disease activity index</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in UCDAItwo weeks,one,three and six months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the simple endoscopic score for CD</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in SEC-CD 3st,6st months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulcerative Colitis endoscopic index of severity</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in UCDEIS 3st and 6st month after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diversity and steady state of the Intestinal mucosa</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline in diversity and steady state of the intestinal mucosa three and six months after intervention</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>co-transplantation of FMT and pectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300ml Bacterial suspension (from 60g fresh stool )given for the first day and 20g pectin given from the second to the sixth day for total five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300ml Bacterial suspension (from 60g fresh stool )given for the first day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>give pectin 20g/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pure give pectin 20g/d for five days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>co-transplantation of FMT and pectin</intervention_name>
    <description>300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days</description>
    <arm_group_label>co-transplantation of FMT and pectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>single fecal microbiota transplantation</intervention_name>
    <description>single fecal microbiota transplantation once the first day</description>
    <arm_group_label>single fecal microbiota transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>pure give pectin 20g/d for five days</intervention_name>
    <description>pure give pectin 20g/d for five days</description>
    <arm_group_label>give pectin 20g/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        for UC

          1. Patients should be in the age range of 18 - 70 years;

          2. Patients should have clinical, imaging, endoscopic and histological diagnosis of UC;

          3. Patients should have a UCDAI score of more than 2 and less than 10 or stage at S1/S2
             in Montreal Rank at enrollment;

          4. Patients receiving a stable dose of concomitant medication (aminosalicylates, oral
             corticosteroids) for at least 4 weeks are eligible;

          5. Patients are capable of providing written informed consent and obtained at the time of
             enrollment;

          6. Patients are willing to adhere to the study visit schedule and other protocol
             requirements.

        for CD:

          1. Patients should be in the age range of 18 - 40 years;

          2. Patients should have clinical, imaging, endoscopic and histological diagnosis of early
             CD*;

          3. Patients should have a CDAI score of more than 150 and less than 400and have a
             C-reactive protein (CRP) level of more than10mg/L at enrollment;

          4. Patients receiving a stable dose of concomitant medication (aminosalicylates, oral
             corticosteroids) for at least 4 weeks are eligible;

          5. Patients are capable of providing written informed consent and obtained at the time of
             enrollment;

          6. Patients are willing to adhere to the study visit schedule and other protocol
             requirements.

        Exclusion Criteria:

          1. Women who are pregnant or lactating at the time of enrollment, or who intend to be
             during the study period

          2. Patients may confuse the findings or there exist any other additional risk history

          3. Patients with end-stage disease or is expected likely to die during the study

          4. Patients are participating in other clinical trials or participated within 3 months
             prior to transplantation

          5. Outbreaks, infectious (viruses, bacteria, parasites, or other microorganisms) colitis,
             scheduled for abdominal surgery,take probiotics / prebiotics / synbiotics / antibiotic
             / PPI (past 1 month) orally, severe anemia (Hbg &lt;6g/dl), heart cerebrovascular
             accident, bypass, stent implantation surgery in the last 6 months, coagulation
             disorders, immune suppression status (defined as: immunosuppressive drugs, a history
             of opportunistic infections within one year recurrent ,oral ulcers, multiple
             lymphadenopathy, neutropenia, etc.), major abdominal transplant surgery in the last 3
             months, have took TNF-Î± monoclonal antibody 2 month before transplantation or planned
             to take within one month after transplantation, a history of megacolon -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning Li, MD</last_name>
    <phone>+86-25-80863736</phone>
    <email>liningrigs@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of General Surgery, Jinling hosptal,Medical School of Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, MD</last_name>
      <phone>+86-25-80863736</phone>
      <email>liningrigs@vip.sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>December 15, 2013</last_update_submitted>
  <last_update_submitted_qc>December 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>weiyao</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

